Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

This study has been completed.

First Received on November 2, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	Palo Alto Medical Foundation
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002064

Purpose

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition	Intervention
Toxoplasmosis, Cerebral HIV Infections	Drug: Pyrimethamine Drug: Clindamycin

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Encephalitis HIV/AIDS Toxoplasmosis

Drug Information available for: Pyrimethamine Clindamycin Clindamycin hydrochloride Clindamycin phosphate Clindamycin Palmitate Hydrochloride Clindamycin palmitate

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002064

Locations

United States, California
Palo Alto Med Foundation
Palo Alto, California, United States, 94301

Sponsors and Collaborators

Palo Alto Medical Foundation

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00002064 History of Changes
Other Study ID Numbers:	021A
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Sulfonamides
Toxoplasmosis
AIDS-Related Opportunistic Infections
Pyrimethamine

Drug Therapy, Combination
Encephalitis
Acquired Immunodeficiency Syndrome
Clindamycin

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Encephalitis
Toxoplasmosis
Toxoplasmosis, Cerebral
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Central Nervous System Viral Diseases

Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Infections
Coccidiosis
Protozoan Infections
Parasitic Diseases
Brain Abscess
Abscess
Suppuration
Infection
Central Nervous System Protozoal Infections
Central Nervous System Parasitic Infections
Clindamycin
Clindamycin-2-phosphate

ClinicalTrials.gov processed this record on February 09, 2012